Roche acquires ForSight VISION4

11 January 2017

Privately-held US ophthalmic drug delivery specialist ForSight VISION4 has announced it has been acquired by Switzerland’s Roche (ROG: SIX).

The company is the fourth venture created by the Menlo Park incubator, ForSight Labs, and was funded entirely by two of the leading venture capital firms in Silicon Valley, Morgenthaler Ventures and Versant Ventures.

Under the terms of the agreement, Roche has acquired ForSight VISION4 for an undisclosed upfront payment and additional earn out payments related to development and commercial milestones. Last year, Allergan acquired ForSight VISION5, another Menlo Park incubator, for $95 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK